Author Archive: BIOtechNOW Editor

Setting the Record Straight on Innovation and Drug Development

stethoscope

Modern biotechnology is a relatively young industry, but in just over 40 years, the entrepreneurs, researchers and investors working in this field have firmly established themselves at the forefront of medical innovation and the search for new cures and therapies for previously untreatable diseases. That’s why it is important that policy proposals designed to respond to the activities of outliers like Turing Pharmaceuticals and Valeant do not hurt America’s leadership in biotechnology innovation and investment. Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , , , ,

Mesothelioma: Once Hopeless Cancer, on the Verge of Promising Advances

MesoAwarenessCarouselGraphic

Mesothelioma, the word, (pronounced mez-uh-thee-lee-oh-muh) is often much better known than the illness it represents. The legal issues surrounding this cancer make mesothelioma, the most expensive keyword on Google (while most keywords cost pennies, the keyword mesothelioma can cost over $300 per click). Mesothelioma, the illness, is a cancer that most often affects the lining of the lung or abdomen; it has no cure and treatment options for patients are few. Prognosis is generally considered Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , , ,

Roll Call: Patient-Centeredness, Comparative Effectiveness, and Value

In Roll Call, Tony Coelho former House Majority Whip, Chairman of the Partnership to Improve Patient Care (PIPC) and author of the Americans with Disabilities Act (ADA) discussed the need for a patient-centered approach to healthcare. Coelho says: “Policymakers talk about the “value” of treatments as if there is one value algorithm that applies to all patients equally. While that may be true in academia, in the real world value is personal. Research on treatment Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , , , ,

Do Outcomes Matter When There Is Chronic Misalignment?

synthetic biology

This piece by Allan L. Shaw was originally published in Life Science Leader. With over $3 trillion in annual healthcare spending, a relatively young population, and shorter life expectancies than other western nations, one would think there would be vast opportunities for the U.S. healthcare industry to rein in costs, weed out inefficiency, and improve outcomes. Instead of yielding to “regression toward the mean,” however, the highest global per capita healthcare machine marches to 20 Read More >

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: , ,

Emerging Themes in Personalized Medicine

1500x500

The adoption of Personalized Medicine is being driven by the omnipresence of Next-Generation Sequencing (NGS), the fast pace of technological innovations in the field, and the President’s Precision Medicine Initiative. To date, however, only a relatively small fraction of the patient population has had their DNA fully sequenced, while a larger segment has undergone limited analysis related to an NGS-based diagnostics test, primarily in the area of oncology. It is expected that this picture will Read More >

Events, Health  |  Leave a comment  |  Email This Post
Tags: , , , ,